MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
复制标题
DOI：
10.1016/j.vaccine.2017.02.012
复制
发表时间：
2017-03-14
期刊：
影响因子：
5.5
通讯作者：
Frieman MB
中科院分区：
文献类型：
--
作者：
Coleman CM;Venkataraman T;Liu YV;Glenn GM;Smith GE;Flyer DC;Frieman MB
中东呼吸综合征冠状病毒（MERS-CoV）于2012年底首次被发现，并已导致1800多例感染和650例死亡。目前没有批准的MERS CoV治疗或疫苗。MERS-CoV刺突（S）蛋白负责受体结合和病毒体进入细胞，是免疫显性的并在体内诱导中和抗体，所有这些使S蛋白成为抗MERS-CoV疫苗的理想靶标。在这项研究中，我们证明了在小鼠中接种重组MERS-CoV S纳米颗粒疫苗和Matrix-M1佐剂组合诱导的保护作用。MERS-CoV S纳米颗粒疫苗产生高滴度的抗S中和抗体，并保护小鼠免受MERS-CoV体内感染。
The Middle East respiratory syndrome coronavirus (MERS-CoV) was first discovered in late 2012 and has gone on to cause over 1800 infections and 650 deaths. There are currently no approved therapeutics or vaccinations for MERS-CoV. The MERS-CoV spike (S) protein is responsible for receptor binding and virion entry to cells, is immunodominant and induces neutralizing antibodies in vivo, all of which, make the S protein an ideal target for anti-MERS-CoV vaccines. In this study, we demonstrate protection induced by vaccination with a recombinant MERS-CoV S nanoparticle vaccine and Matrix-M1 adjuvant combination in mice. The MERS-CoV S nanoparticle vaccine produced high titer anti-S neutralizing antibody and protected mice from MERS-CoV infection in vivo.